Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Seminars in Oncology

• Publication date

  2011-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.seminoncol.2011.04.008PMID 21810505
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.

  2011cited by this paper
• Breast cancer risk reduction.

  2010cited by this paper
• Genetic/familial high-risk assessment: breast and ovarian.

  2010cited by this paper
• Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes

  2010cited by this paper
• Beyond triple-negative breast cancer: the need to define new subtypes

  2010cited by this paper
• Distress among women receiving uninformative BRCA1/2 results: 12‐month outcomes

  2009cited by this paper
• Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.

  2009cited by this paper
• Cowden Syndrome: A Critical Review of the Clinical Literature

  2009cited by this paper
• A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history

  2009cited by this paper
• UvA-DARE ( Digital Academic Repository ) A method to assess the clinical significance of unclassified variants in the BRCA 1 and BRCA 2 genes based on cancer family history

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

  2009cited by this paper
• Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

  2009cited by this paper
• Disentangling the Babylonian speech confusion in genetic counseling: An analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic

  2009cited by this paper
• Assessment of functional effects of unclassified genetic variants

  2008cited by this paper
• Genetic variants of uncertain significance: flies in the ointment.

  2008cited by this paper
• Genetic evidence and integration of various data sources for classifying uncertain variants into a single model

  2008cited by this paper
• Breast cancer risk reduction.

  2007cited by this paper
• American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography

  2007cited by this paper
• Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

  2007cited by this paper
• Limited family structure and BRCA gene mutation status in single cases of breast cancer.

  2007cited by this paper
• A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

  2007cited by this paper
• Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines

  2005cited by this paper
• 'A variant of uncertain significance' and the proliferation of human disease gene databases

  2005cited by this paper
• Evaluation and management of women with BRCA1/2 mutations.

  2005cited by this paper
• The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.

  2005cited by this paper
• Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

  2005cited by this paper
• What’s the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer

  2005cited by this paper
• Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

  2004cited by this paper
• Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer

  2004cited by this paper
• Variants of Uncertain Clinical Significance as a Result of BRCA1/2 Testing: Impact of an Ambiguous Breast Cancer Risk Message

  2004cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

  2003cited by this paper
• TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.

  2003cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

  2002cited by this paper
• Clinical Interpretation and Recommendations for Patients with a Variant of Uncertain Significance in BRCA1 or BRCA2: A Survey of Genetic Counseling Practice

  2002cited by this paper
• BRCA1/2 testing: complex themes in result interpretation.

  2001cited by this paper
• What's the message.

  2000cited by this paper
• P53 germline mutations in childhood cancers and cancer risk for carrier individuals

  2000cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction

  1994cited by this paper
• Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

  1989cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper

• Identification of Germinal Mutations in Eight Exons of the BRCA1 Gene in Breast Cancer Patients in the State of Amazonas, Using Direct Sequencing

  2020cites this paper
• How patients deal with an ambiguous medical test: Decision-making after genetic testing.

  2020cites this paper
• A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results

  2020cites this paper
• Functional studies of genetic variants of unknown significance

  2019cites this paper
• A meta-analysis of zinc levels in breast cancer.

  2019cites this paper
• BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report

  2017cites this paper
• Evaluation of laboratory perspectives on hereditary cancer panels

  2016cites this paper
• Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry

  2016cites this paper
• Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing

  2015cites this paper
• A preliminary investigation of genetic counselors’ information needs when receiving a variant of uncertain significance result: a mixed methods study

  2015cites this paper
• Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?

  2014cites this paper
• Genetic and Genomic Factors in Breast Cancer

  2013cites this paper
• Large numbers of individuals are required to classify and define risk for rare variants in known cancer risk genes

  2013cites this paper
• Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.

  2013cites this paper
• BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.

  2011cites this paper